Cancer Invest. 2009 Feb;27(2):221-6.

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL.

Source

Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA. chingj@mail.nih.gov

Abstract

ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.

PMID:: 19235596; [PubMed - indexed for MEDLINE]
PMCID:: PMC2648132

Free PMC Article

Images from this publication.See all images (1) Free text

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Related citations in PubMed

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. [Breast Cancer Res Treat. 2010]
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Breast Cancer Res Treat. 2010 Jul; 122(1):181-8. Epub 2010 Apr 2.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. [J Clin Oncol. 2005]
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, et al. J Clin Oncol. 2005 Dec 1; 23(34):8580-7.
Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. [J Oral Maxillofac Surg. 2007]
Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. J Oral Maxillofac Surg. 2007 Jul; 65(7):1328-31.
Review A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. [Clin Ther. 2007]
Review A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. Clin Ther. 2007 Aug; 29(8):1548-58.
Review Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. [Am J Health Syst Pharm. 2009]
Review Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.
Gebara SN, Moubayed H. Am J Health Syst Pharm. 2009 Sep 1; 66(17):1541-7.

See reviews... See all...

Cited by 7 PubMed Central articles

Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. [BMC Musculoskelet Disord. 2011]
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study.
Borromeo GL, Brand C, Clement JG, McCullough M, Thomson W, Flitzanis E, Wark JD. BMC Musculoskelet Disord. 2011 Apr 10; 12:71. Epub 2011 Apr 10.
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. [Ther Clin Risk Manag. 2010]
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.
English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD. Ther Clin Risk Manag. 2010 Nov 19; 6:579-83. Epub 2010 Nov 19.
Review Updates on osteonecrosis of the jaw. [Curr Opin Support Palliat Care...]
Review Updates on osteonecrosis of the jaw.
Yamashita J, McCauley LK, Van Poznak C. Curr Opin Support Palliat Care. 2010 Sep; 4(3):200-6.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic c...
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest. 2009 Feb ;27(2):221-6.

PubMed
Regional metabolic changes in the hippocampus and posterior cingulate area detec...
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
Acta Radiol. 2009 Apr ;50(3):312-9.

PubMed
Gemcitabine-based doublets versus single-agent therapy for elderly patients with...
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.
Cancer. 2009 May 1 ;115(9):1924-31.

PubMed
Rheological blends for drug delivery. I. Characterization in vitro.
Rheological blends for drug delivery. I. Characterization in vitro.
J Biomed Mater Res A. 2010 Feb ;92(2):575-85.

PubMed
Development of a cell-derived matrix: effects of epidermal growth factor in chem...
Development of a cell-derived matrix: effects of epidermal growth factor in chemically defined culture.
J Biomed Mater Res A. 2010 Feb ;92(2):533-41.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 7 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information